News

News

WIB_icon

Low-Molecular-Weight Heparin Fails to Boost Live Birth Rates in Women with Recurrent Miscarriage

Antithrombotic medications are often prescribed to women with histories of unexplained recurrent miscarriages, although there is little evidence of the efficacy of this approach....

LRF Awards Grants, NCI Awards UT Southwestern Funding, and more

LRF Awards Grants to Study Lymphoma in Adolescent, Young Adult Patients As part of a partnership with The Paul Foundation on Critical Adolescent and Young...
WIB_icon

Ibritumomab Tiuxetan Ups Survival in Tough-to-Treat Diffuse Large B-Cell Lymphoma

Many patients with aggressive B-cell non-Hodgkin lymphoma (NHL) are cured of the disease after short-course chemotherapy and radiation. Certain adverse risk factors, though, make relapse more likely. Ibritumomab tiuxetan as add-on...
WIB_icon

Brentuximab Vedotin Active in Relapsed/Refractory B-Cell Lymphoma

For patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for transplant or fail to respond to salvage regimens, treatment with brentuximab...

NIH Awards Several Grants for Deciphering Gene Regulation, and more

Multiple Researchers Awarded NIH Grants to Decipher the Language of Gene Regulation The National Institutes of Health has awarded multiple grants totaling more than $28 million aimed...

A Zebrafish and Enhanced Imaging Captures How Blood Stem Cells Take Root

A research team from Boston Children Hospital’s Stem Cell Research Program has provided the first direct glimpse into how blood stem cells take root...

FDA Expands Use of Ibrutinib, Fast Track Designation Granted to SGX301, and more

FDA Expands Use  of Ibrutinib for Waldenström Macroglobulinemia The U.S. Food and Drug Administration (FDA) approved the expanded use of ibrutinib to treat Waldenström macroglobulinemia (WM),...

ELOQUENT-2, SUSTAIN, and more

LEUKEMIA Selected by David Steensma, MD Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (NCT02267278) Study Design: Open-label, single-group assignment safety/efficacy study Study Start Date: January 2015 ...

The Debate Rages on: Is Omitting Radiation Therapy from Hodgkin Lymphoma Good for Patients?

Although Hodgkin lymphoma (HL) is frequently treated with a combination of chemotherapy and radiation therapy, there is a movement towards omitting radiation therapy altogether....

Is It Time to Reconsider Allogeneic SCT in NPM1-Mutant AML?

Allogeneic stem cell transplantation (SCT) significantly improved rates of relapse-free survival (RFS), but not overall survival (OS) in patients with acute myeloid leukemia (AML)...
Advertisement

Current Issue

April 2019, Volume 5, Issue 5

This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.